Summary
Biopsy specimens of 55 human mammary carcinomas (38 primary and 17 metastatic) were assayed for prolactin receptors (PrlR). Prolactin bound specifically to 32 (58%) of the tumor biopsy specimens. The apparent K d for PrlR in individual tumors ranged from 15 pM to 2. 3 nM (mean 600 pM,n = 5) and the concentration of PrlR ranged from 0 to 44.5 fmoles/mg protein. Estrogen receptors (ERP) were also detected in 28 of the 32 tumors which had PrlR. Overall, there was no correlation between PrlR and ERP. However, the mean concentration of PrlR was significantly higher (p <0.01) in tumors with 6–100 fmoles/mg protein ERP (∼ 13 fmoles PrlR) than in tumors with either <6 or >250 fmoles ERP (4.0 ± 0.4 and 6.5 ± 1.8 respectively fmoles PrlR). Analysis of PrlR concentration as a function of patient age also showed no overall correlation, but the mean PrlR in tumors from women aged 60–70 was significantly higher (p <0.01) than in those from either younger or older women. A higher concentration of PrlR was observed in tumors which were classified histologically as medium or well differentiated (6.1 ± 1.2 and 11.1 ± 2.1, respectively) than in those classified as poorly differentiated (3.3 ± 1.2) (p <0.03). There was a negative correlation between PrlR concentration and membrane yield from the tumors (r = 0.43,p <0.002). The membrane yield correlated with the ratio of tumor cells to stroma (histologically) (r = 0.63,p <0.001). In tumors from 12 patients with metastatic disease on whom follow up after endocrine-related therapy was available, the mean PrlR concentration was significantly higher in the non-responding group (8.2 ± 3.0) than in the responding group (3.4 ± 4.2,p = 0.05).
References
Venter BR: Prolactin binding to human mammary tumors as a function of estrogen receptor concentration and patient age (abstract). Fed Proc 38:349, 1979
McGuire WL, Carbone PP, Sears ME, Escher GC: Estrogen receptors in human breast cancer: An overview.In: WL McGuire, PP Carbone, EP Volmer (eds): Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975, pp 1–7
Horwitz KB, McGuire WL, Pearson OH, Segaloff A: Predicting response to endocrine therapy in human breast cancer: A hypothesis. Science 89:726–727, 1975
Costlow ME, Buschow RA, McGuire WL: Prolactin receptors in 7,12-dimethylbenz(a)anthracene-induced mammary tumors following endocrine ablation. Cancer Res 36:3941–3943, 1976
Sinha D, Cooper D, Dao TL: The nature of estrogen and prolactin effect on mammary tumorigenesis. Cancer Res 33:411–414, 1973
Talwalder PK, Meites J, Mezeino H: Mammary tumor induction by estrogen or anterior pituitary hormones in ovariectomized rats given 7,12-dimethyl-1,2-benzathracene. Proc Soc Exp Biol Med 116:531–534, 1964
Asselin J, Kelly PA, Caron MC, Labrie F: Control of hormone receptor levels and growth of 7,12-dimethyl-benz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin. Endocrinology 101:666–671, 1977
Horwitz KB, McGuire WL: Progesterone and progesterone receptors in experimental breast cancer. Cancer Res 37:1733–1738, 1977
Dilley WG, Kister SG: In vitro stimulation of human breast tissue by human prolactin. J Natl Cancer Inst 55:35–36, 1975
Shiu RPC, Friesen HG: Properties of a prolactin receptor from the rabbit mammary gland. Biochem J 140:301–311, 1974
Barrett A, DeSouza I, Morgan L, Tovey F, Hobbs JR: A breast carcinoma dependent on human placental lactogen. The Lancet June 14, 1975, p 1374
Holdaway IM, Friesen HG: Hormone binding by human mammary carcinoma. Cancer Res 37:1946–1952, 1977
Stagner JI, Jochimsen PR, Sherman BM: Lactogenic hormone binding to human breast cancer (abstract). Clin Res Abstracts 25:302A, 1977
Schultz CS, Ebner KE: α-lactalbumin levels in human mammary tumors, sera, and mammary cell culture lines. Cancer Res 37:4489–4492, 1977
Lewis UJ, Singh RNP: Recovery of prolactin from human pituitary glands.In: JL Pasteels and C Robyn (eds): Human Prolactin: Proceedings of the International Symposium on Human Prolactin, Brussels, June 12–14, 1973. Elsevier, New York, 1973, pp 1–10
Scatchard B: The attractions of proteins for small molecules and ions. Annals NY Acad Sci 51:660, 1949
Schneider SL, Dao TL: Effect of Ca2+ and salt on forms of estradiol cytoplasmic receptor in human neoplastic breast tissue. Cancer Res 37:382–387, 1977
Avruch J, Wallach DFH: Preparation and properties of plasma membrane and endoplasmic reticulum fragments from isolated rat fat cells. Biochim Biophys Acta 233:334–347, 1971
Wittliff JL, Beatty BW, Savlov ED, Patterson WB, Cooper RA Jr: Estrogen receptors and hormone dependency. in human breast cancer. Recent Results Cancer Res 57:59–77, 1976
Knight WA III, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669–4671, 1977
Frank S, Ralphs DNL, Seagroatt V, Jacobs HS: Prolactin concentrations in patients with breast cancer. Br Med J 4:320–321, 1974
Hill P, Wynder EL, Kuman H, Helman P, Rona G, Kuna K: Prolactin levels in populations at risk for breast cancer. Cancer Res 36:4102–4106, 1976
Kwa HG, De Jong-Bakker M, Engelsman E, Cleton FJ: Plasma prolactin in human breast cancer. Lancet 1:433–435, 1974
Leung CK, Shiu RPC. Required presence of both estrogen and pituitary factors for the growth of human breast cancer cells in athymic nude mice. Cancer Res 41:546–551, 1981
Author information
Authors and Affiliations
Additional information
Address for reprints: Dr. Barbara Rae-Venter, Department of Surgery, University of Texas Medical Branch, Galveston, TX 77550.
Rights and permissions
About this article
Cite this article
Rae-Venter, B., Nemoto, T., Schneider, S.L. et al. Prolactin binding by human mammary carcinoma: Relationship to estrogen receptor protein concentration and patient age. Breast Cancer Res Tr 1, 233–243 (1981). https://doi.org/10.1007/BF01806263
Issue Date:
DOI: https://doi.org/10.1007/BF01806263